Equities

Concord Biotech Ltd

CONCORDBIO:NSI

Concord Biotech Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,249.95
  • Today's Change-9.15 / -0.41%
  • Shares traded54.12k
  • 1 Year change+127.84%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 05:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments2,8171,8041,628
Total Receivables, Net3,7893,2312,602
Total Inventory2,1562,1361,976
Prepaid expenses735548
Other current assets, total1275173
Total current assets8,9627,2776,327
Property, plant & equipment, net7,8657,6556,436
Goodwill, net------
Intangibles, net3.201.9836
Long term investments3110328
Note receivable - long term1252736
Other long term assets2276266
Total assets17,00715,14013,128
LIABILITIES
Accounts payable944938831
Accrued expenses1.042.603.63
Notes payable/short-term debt0043
Current portion long-term debt/capital leases79251266
Other current liabilities, total398726408
Total current liabilities1,4221,9181,552
Total long term debt1964316
Total debt97315625
Deferred income tax281234210
Minority interest------
Other liabilities, total202319
Total liabilities1,7412,2402,096
SHAREHOLDERS EQUITY
Common stock10510595
Additional paid-in capital820820829
Retained earnings (accumulated deficit)14,34211,97610,108
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity15,26612,90011,032
Total liabilities & shareholders' equity17,00715,14013,128
Total common shares outstanding105105105
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.